This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Castellani, S. Articles by Neri Serneri, G. G. Search for Related Content PubMed PubMed Citation Articles by Castellani, S. Articles by Neri Serneri, G. G.

Thromboxane inhibition improves renal perfusion and excretory function in severe congestive heart failure

Sergio Castellani, MD^*,*, Rita Paniccia, PhD^*, Claudia Di Serio, PhD, Giuseppe La Cava, MD, Loredana Poggesi, MD^*, Stefano Fumagalli, MD, Gian Franco Gensini, MD^* and Gian Gastone Neri Serneri, MD^*

^* Sezione Clinica Medica Generale e Cardiologia, Firenze, Italy
Sezione Gerontologia e Geriatria, Dipartimento di Area Critica Medico Chirurgica, Firenze, Italy
Sezione di Medicina Nucleare, Dipartimento di Fisiopatologia Clinica, Università degli Studi di Firenze and Azienda Ospedaliera Careggi, FirenzeItaly

View larger version (33K): [in a new window]   Figure 1 Urinary thromboxane B2 (UTxB2) levels (ng/g UCr/24 h) during the two treatments: placebo (open bars) and active treatment (hatched bars). *p < 0.01 vs. day 6 of placebo; °p < 0.01 vs. day 8 of placebo; p < 0.01 vs. baseline.

View larger version (38K): [in a new window]   Figure 2 Effects of thromboxane A2 inhibition on renal hemodynamics. Open bars = placebo; hatched bars = active treatment. *p < 0.05 vs. day 8 of placebo; **p < 0.01 vs. day 8 of placebo. ERPF = effective renal plasma flow; FF = filtration fraction; GFR = glomerular filtration rate; RVR = renal vascular resistance.